Vivos Therapeutics ( (VVOS) ) has released a notification of late filing.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Vivos Therapeutics, Inc. has filed a Form 12b-25 to notify the delay of its Form 10-Q (Quarter Report) for the financial period ending September 30, 2025. The delay is primarily due to the acquisition of The Sleep Center of Nevada, which requires additional time for the consolidation of financial statements. The company expects to file the report within the five-day extension period. Financially, Vivos anticipates a significant increase in revenue and expenses, leading to a higher net loss compared to the previous year, largely driven by the new acquisition. The notification was signed by Bradford Amman, Chief Financial Officer, who assures ongoing compliance efforts.
The most recent analyst rating on (VVOS) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Vivos Therapeutics stock, see the VVOS Stock Forecast page.
Spark’s Take on VVOS Stock
According to Spark, TipRanks’ AI Analyst, VVOS is a Neutral.
Vivos Therapeutics faces significant challenges with financial performance and technical indicators showing bearish trends. While strategic initiatives from the earnings call offer potential, current valuation metrics and financial struggles weigh heavily on the stock’s outlook.
To see Spark’s full report on VVOS stock, click here.
More about Vivos Therapeutics
Average Trading Volume: 282,385
Technical Sentiment Signal: Sell
Current Market Cap: $18.91M
See more data about VVOS stock on TipRanks’ Stock Analysis page.